Suppr超能文献

聚乳酸-羟基乙酸共聚物微球在肝细胞癌动物模型经动脉化疗栓塞中的应用。

Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma.

作者信息

Qian Jun, Truebenbach Jochen, Graepler Florian, Pereira Philippe, Huppert Peter, Eul Thomas, Wiemann Gundula, Claussen Claus

机构信息

Department of Diagnostic Radiology, Eberhard-Karls-University Tubingen, Germany.

出版信息

World J Gastroenterol. 2003 Jan;9(1):94-8. doi: 10.3748/wjg.v9.i1.94.

Abstract

AIM

To introduce an animal model of hepatocellular carcinoma (HCC) in ACI-rats, and to evaluate the therapeutic effects of Poly-lactide-co-glycolide (Plcg) -microspheres in the transarterial chemoembolization (TACE) in this model, as well the value of this model in the experiments of interventional therapy.

METHODS

Subcapsular implantation of a solid Morris Hepatoma 3 924A (1 mm(3)) in the livers was carried out in 11 male ACI-rats. The tumor volume (V1) was measured by magnetic resonance imaging (MRI) (13 days after implantation). After laparotomy and retrograde placement of catheter into the gastroduodenal artery (14 days after implantation), the following protocols of interventional treatment were performed: (A) mitomycin C+Poly-lactide-co-glycolide (Plcg)-microspheres (n=4); (B) 0.9 % NaCl (control group, n=7). 13 days after these therapies the change of the tumor volume (V2) was determined by MRI again.

RESULTS

The success rate of tumor implantation reached to 100 %. The mean tumor volume before TACE (V1) were 0.082 cm(3) in group A and 0.096 cm(3) in group B respectively. The mean tumor volume after TACE (V2) were 0.230 cm(3) in group A and 1.347 cm(3) in group B respectively. The mean V2/V1 were 2.860 in group A and 27.120 in group B respectively. Compared to the control group (group B), groups A showed a significant reduction of tumor growth (P=0.004) in the period of observation.

CONCLUSION

The growth of liver tumor could be obviously prevented by utilizing Plcg-mitomycin-microspheres in TACE in animal model. This rat model of HCC is suitable for the experimental studies of interventional therapy.

摘要

目的

介绍一种在 ACI 大鼠中建立肝细胞癌(HCC)的动物模型,并评估聚丙交酯-乙交酯(Plcg)微球在该模型经动脉化疗栓塞术(TACE)中的治疗效果,以及该模型在介入治疗实验中的价值。

方法

对 11 只雄性 ACI 大鼠进行肝包膜下植入实体型 Morris 肝癌 3924A(1mm³)。通过磁共振成像(MRI)测量肿瘤体积(V1)(植入后 13 天)。植入后 14 天,剖腹并将导管逆行置入胃十二指肠动脉,然后进行以下介入治疗方案:(A)丝裂霉素 C + 聚丙交酯-乙交酯(Plcg)微球(n = 4);(B)0.9%氯化钠(对照组,n = 7)。这些治疗 13 天后,再次通过 MRI 测定肿瘤体积变化(V2)。

结果

肿瘤植入成功率达 至 100%。TACE 前 A 组平均肿瘤体积(V1)为 0.082cm³,B 组为 0.096cm³。TACE 后 A 组平均肿瘤体积(V2)为 0.230cm³,B 组为 1.347cm³。A 组平均 V2/V1 为 2.860,B 组为 27.120。与对照组(B 组)相比,A 组在观察期内肿瘤生长明显减缓(P = 0.004)。

结论

在动物模型的 TACE 中使用 Plcg - 丝裂霉素微球可明显抑制肝肿瘤生长。这种 HCC 大鼠模型适用于介入治疗的实验研究。

相似文献

引用本文的文献

2
Liver Cancer: Current and Future Trends Using Biomaterials.肝癌:生物材料的现状与未来趋势
Cancers (Basel). 2019 Dec 16;11(12):2026. doi: 10.3390/cancers11122026.
10
Hepatocellular carcinoma: insight from animal models.肝细胞癌:动物模型的研究进展。
Nat Rev Gastroenterol Hepatol. 2011 Oct 25;9(1):32-43. doi: 10.1038/nrgastro.2011.196.

本文引用的文献

1
Surgery and ablative therapy for hepatocellular carcinoma.肝细胞癌的手术及消融治疗
J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S130-7. doi: 10.1097/00004836-200211002-00009.
8
Hepatocellular carcinoma: an Asian perspective.肝细胞癌:亚洲视角
Dig Dis. 2001;19(4):263-8. doi: 10.1159/000050692.
10
Hepatocellular carcinoma--cause, treatment and metastasis.肝细胞癌——病因、治疗与转移
World J Gastroenterol. 2001 Aug;7(4):445-54. doi: 10.3748/wjg.v7.i4.445.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验